Abstracts Clinical Lymphoma, Myeloma & Leukemia September 2023 S412 HL-393 5‑year Overall Survival Rate of Patients With Classical Hodgkin Lymphoma in Armenia Levon Evoyan MD1, Gevorg Tamamyan PhD1,2,3,4, Arusyak Ivanyan MD1, Anahit Ter-Grigoryan MD1, Miranush Saaryan MD1, Samvel Danelyan MD1, Astghik Voskanyan MD1,2 1Hematology Center after Prof. Yeolyan, Yerevan, Armenia. 2Immune Oncology Research Institute, Yerevan, Armenia. 3Pediatric Cancer and Blood Disorders Center, Yerevan, Armenia. 4Department of Pediatric Oncology and Hematology, Yerevan State Medical University, Yerevan, Armenia Background: Hodgkin lymphoma (HL) is one of the most curable malignancies with a 5-year survival of over 80%. Classical HL (cHL) accounts for 95% of all HL and is subdivided into four subgroups: nodular sclerosis (NSHL), lymphocyte-rich (LRHL), mixed cellularity (MCHL), and lymphocyte-depleted (LDHL). Aims: The aim of our retrospective study was to determine the 5-year overall survival rate of patients with cHL treated at the Hematology Center after Prof. R. Yeolyan in Armenia. Methods: The data were collected from the medical records of all patients diagnosed with cHL at the Hematology Center after Prof. R. Yeolyan in Armenia from January 01, 2015, to December 31, 2020. Survival analysis was performed using the Kaplan-Meier method. Results: Over the five-year period, 212 patients were diagnosed with cHL with a median age of 45 years (20–83 years) at the time of diagnosis. The male-to-female ratio was 1.09:1. Histological subtypes included NSHL (54.8%), MCHL (35.3%), LRHL (8.49%), and LDHL (1.41%). At the time of diagnosis, 56% had advanced disease and 58% had B symptoms. Sixty-seven percent of patients received the initial treatment with ABVD (doxorubicin hydrochloride [Adriamycin], bleomycin sulfate, vinblastine sulfate, and dacarbazine), and 33% with BEACOPP (bleomycin sulfate, etoposide phosphate, doxorubicin hydrochloride [Adriamycin], cyclophosphamide, vincristine sulfate [Oncovin], procarbazine hydrochloride, and prednisone) chemotherapy regimens. The maximum follow-up duration was 93 months; 5-year overall survival was 91%. Conclusions: Despite that Armenia is a resource-limited country, the 5-year overall survival in this cohort of patients with cHL was comparable to the developed world. Keywords: HL, classical Hodgkin lymphoma, treatment, 5-year OS HL-456 A Retrospective Analysis of Impact of EBV Status on Outcomes in Hodgkin Lymphoma Elif Yilmaz MD1,2, Heather Reves BA1, Aimaz Afrough MD1,2, Julio Alvarenga MD1,2, Larry Anderson Jr MD, PhD1,2, Robert Collins MD1,2, Stephen Chung MD1,2, Gurbakhash Kaur MD1,2, Adeel Khan MD, MPH, MS1,2, Yazan Madanat MD1,2, Alka Mallik MD1,2, Heather Wolfe MD1,2, Praveen Ramakrishnan MD1,2, Farrukh T. Awan MD1,2 1UT Southwestern Medical Center, Dallas, USA. 2Harold C. Simmons Comprehensive Cancer Center, Dallas, USA Context: About 30-40% of all new cases of Hodgkin lymphoma (HL) in developed countries are associated with Epstein-Barr virus (EBV) infection. Retrospective studies have shown conflicting data regarding the impact of EBV association on outcomes in HL. In this study, we aimed to compare baseline disease characteristics, socioeconomic status, and clinical outcomes between EBV-positive (EBV+) and EBV-negative (EBV-) HL patients. Design: We conducted an Institutional Review Board-approved retrospective review of HL patients treated within a tertiary care center from 2009 to 2022. Patients with HIV infection were excluded. We defined EBV association as EBER and/or LMP-1 positivity on diagnostic biopsy samples. Progression-free survival and overall survival (OS) from initiation of first treatment were calculated using the KaplanMeier method and compared using log-rank test. Multivariate hazard regression analysis was applied to determine the variables associated with outcomes. Results: A total of 175 patients were included (108 EBV+ HL, 67 EBV- HL). Patients with EBV+ HL presented with higher median age (47 vs 35; P<0.0001); higher ratio of International Prognostic Score (IPS) of 4–7 (43% vs 19%; P=0.005), bone marrow involvement (34% vs 6%; P<0.001), and Eastern Cooperative Oncology Group performance status ≥ 2 (21% vs 6%; P=0.01) compared to EBV- HL patients. Patient demographics (including gender, ethnicity, distance to hospital and median household income), rate of treatment delays and opportunistic infections during therapy were similar between the 2 groups. Both 2-year and 5-year OS rates of EBV+ HL were worse compared to EBV- HL (86% vs 97.1% and 69% vs 93.1%, respectively; P<0.0001). On multivariate regression analysis, factors associated with OS included age (HR 1.04; 95% CI: 1.006–1.08), IPS of 4-7 (HR 2.3; 95% CI: 1.4–3.8) and delays during treatment (HR 6.6; 95% CI: 1.4–31.1). EBV positivity was not significantly associated with OS after other prognostic factors were controlled (HR 1.6; 95% CI: 0.5–5.4). Conclusions: EBV+ HL patients have an inferior OS compared to patients with EBV- HL. Our study shows that the inferior survival rate is driven by presence of higher-risk disease characteristics at diagnosis in EBV+ HL and not by increased rate of therapy-related complications or socioeconomic disparities. Keywords: HL, Epstein-Barr, EBV, lymphoma, Hodgkin HL-561 Treating Refractory Immune Thrombocytopenia (ITP) in the Context of Concomitant Papillary Thyroid Carcinoma (PTC) and Hodgkin Lymphoma (HL): A Rare Case Report Basma Atef MD1, Yasmine Shaaban MD1, Mohamed Elbogdady MD1, May Denewer MD1, Asmaa Mohsen MScs1, Esraa Jamal MScs1, Maged Saafan MScs1, Ahmed Talaat MScs1, Ahmed Elazab MScs1, Malaka Awad MScs1, Manal Atef MScs2, Atef Aly MScs1, Raghda I.F. Khalifa MBBCh1, Noreen M.A Elbayoumi MBBCh1, Noha M. Badawy MBBCh1, Arwa Abbas MBBCh1,
RkJQdWJsaXNoZXIy MTk3NTQxMg==